In patients with BRAFV600E mCRC tumors that are treated with BRAF-inhibitor monotherapy, feedback reactivation of EGFR is observed, thereby providing rationale for combination with cetuximab or panitumumab.66 Data from cell lines, in vivo studies in BRAF-mutant CRC murine models,67 and clinical data in BRAFV600E mCRC68,69 indicate that combined inhibition of BRAF and EGFR is synergistic. Here, EGFR is linked to colorectal carcinoma.